Instituto de Investigación Biomédica de A Coruña (INIBIC)
Centro de investigación
Mariano
Provencio Pulla
Publicaciones en las que colabora con Mariano Provencio Pulla (48)
2024
-
Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry
Archivos de Bronconeumologia, Vol. 60, pp. S38-S45
-
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC
Lung Cancer, Vol. 194
-
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry
Lung Cancer, Vol. 190
-
Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk
Lung Cancer, Vol. 195
-
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1647-1663
-
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 25, Núm. 11, pp. 1453-1464
-
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049
2023
-
Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study
ERJ Open Research, Vol. 9, Núm. 6
-
Occupation as a risk factor of small cell lung cancer
Scientific Reports, Vol. 13, Núm. 1
-
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
Annals of Oncology, Vol. 34, Núm. 10, pp. 920-933
2022
-
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
BMC Cancer, Vol. 22, Núm. 1
-
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
Journal of Clinical Oncology, Vol. 71
-
Radon, Tobacco Exposure and Non-Small Cell Lung Cancer Risk Related to BER and NER Genetic Polymorphisms
Archivos de Bronconeumologia, Vol. 58, Núm. 4, pp. 311-322
-
Residential Radon and Small Cell Lung Cancer. Final Results of the Small Cell Study
Archivos de Bronconeumologia, Vol. 58, Núm. 7, pp. 542-546
-
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
Journal for immunotherapy of cancer, Vol. 10, Núm. 9
2021
-
Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study
Translational Lung Cancer Research, Vol. 10, Núm. 10, pp. 3902-3911
-
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the thoracic tumor registry
PLoS ONE, Vol. 16, Núm. 6 June
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
-
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
BMC Cancer, Vol. 21, Núm. 1
2020
-
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148